Background of the study: Difficult lies at the core of drug producer successful operation. Laboratory testing, which is compulsory by the CGMP regulations are required to check that components, containers and closures, in-process materials, and finished products conform to specifications, including stability specifications. Objective of the study: The objective of the investigation procedure should clearly state when the investigation is required, and define OOS, OOT, and aberrant results. OOS results are most often generated due to laboratory or manufacturing-related errors, the setting of inappropriate specifications, or poor method development. Materials and Methods: The current work is an effort to deliberate several aspects of finding the root cause for the OOS during the finished product analysis by using HPLC. Results and Discussion: Product's individual unknown impurity was not in specification limit and, hence study carried out to find the root cause. Conclusion: After conducting detail investigation it was proved that an analyst conducted the analysis of the product after the due date to expiry.
INTRODUCTION

Laboratory errors
Laboratory errors occur when analysts make mistakes in following the method of analysis, use incorrect standards, and/or simply miscalculate the data. Laboratory errors must be determined through a failure investigation to identify the cause of the OOS. Once the nature of the OOS result has been identified it can be classified into one of the three categories OOS, OOT, Atypical results. The enquiry may vary with the object under investigation 1 . In pharmaceutical industry, out-of-specification (OOS) test results are results that (after rounding off) fall outside the specifications of established acceptance criteria. By analogy, measurement or test results obtained in other industries and such fields as environmental and/or food analysis, which do not comply with regulatory, specification or legislation limits, can be named also OOS test results. The problem of OOS test results was known for analysts working in quality control laboratories since the 1920s, but it was not understood until the 1990s that a lack of statistical and metrological thinking is the main aspect of the problem. In 1993, Barr Laboratories (a generic-drug manufacturer) was used by US government regarding a set of issues influencing the product quality, including the way the company dealt with OOS test results. Among the issues were averaging OOS with inspecification test result values to get a passing result, conducting multiple retests with no defined end point, performing inadequate failure investigations, maintaining an ineffective program for process validation and lacking analytical method validation, etc. Judge Wolin's ruling (the Barr Decision) was that following an OOS test result, an investigation must be initiated before any retesting can be done. Identifying OOS test results is described in the FDA Guidance as the laboratory (Phase 1) investigation [2] [3] [4] . It includes responsibility of the analyst and his or her supervisor, conditions of the testing in the laboratory, etc 5 . Identifying OOS test results using investigating tools in currently, the majority of analysts realize that the measurement uncertainty concept is very important because of necessity to balance the cost of measurements versus the product quality risk. For example, to assess compliance of a test result within legislation limits, the analyst should report not only an analyte concentration, but also the associated measurement uncertainty 6, 7 . The value obtained by subtracting the uncertainty from the reported concentration is used to assess compliance with the upper legislation limit. When the compliance assessment is made on the basis of a measurement result accompanied by information on the uncertainty associated with the result, the rules Developed in the EURACHEM/CITAC Guide are applicable for identifying OOS test results. Similar rules are included in the ILAC Guidelines. JCGM Guide on the role of measurement uncertainty in conformity assessment is under development 8 . After identification of an OOS test result, it is important to determine its root causes with the purpose to avoid any repetition of the occurrence when the appearance of a next OOS test result is possible or even inevitable 9 . The FDA Guidance formulates recommendations for such incidences including production process review, additional laboratory testing using a pre-defined procedure, reporting testing results, and concluding the investigation with identification of the root causes. Thus, this document establishes an empirical organizational approach to the full-scale (Phase 2) investigation and decisions which can be accepted at the different stages of this investigation [10] [11] [12] . The FDA and other regulatory agencies consider the integrity of laboratory data to be an integral part of the drug manufacturing process. Deficiencies of out-ofspecification (OOS) investigations continue to be the major cause of warning letters in the pharmaceutical industry. The regulatory agencies require that OOS, outof-trend (OOT), or aberrant results be investigated. an effective and compliant quality management system will ensure thorough, timely, unbiased, well-documented, scientifically sound investigations for OOS, OOT, and aberrant results, which will ensure, if a root cause can be assigned, the implementation of appropriate corrective and preventative actions 13 . The challenge for many firms is having a clearly outlined and well-organized process that is well understood by analysts, supervisors, and manufacturing personnel and that provides for clear, concise, complete documentation. A lack of consistency in the approaches to investigations and root-cause analyses also leads to weak, inconclusive investigations. The flow of investigation is represented in figure 1 above. The firm's procedure for failure investigations should discuss the types of errors that may arise and how to deal with them, describe how to investigate failures, and cover timeliness of assessments, including the following: scope, roles and responsibilities, definitions, investigation procedure (phases of the investigation), documentation, corrective and preventative action, and trend analysis. The focus of this study is an OOS investigation; however, the principles are applicable to all analytical laboratory investigations. The exact cause of analyst error or mistake can be difficult to determine specifically and it is unrealistic to expect that analyst error will always be determined and documented. Nevertheless, a laboratory investigation consists of more than a retest. The inability to identify an error's cause with confidence affects retesting procedures, not the investigation inquiry required for the initial OOS result 14 . The firm's analyst should follow a written procedure, checking off each step as it is completed during the analytical procedure. We expect laboratory test data to be recorded directly documented, use of scrap paper and loose paper must be avoided. These common sense measures enhance the accuracy and integrity of data. Review and evaluate the laboratory SOP for product failure investigations. Specific procedures must be followed when single and multiple OOS results are investigated. For the single OOS result the investigation should include the following steps and these inquiries must be conducted before there is a retest of the sample and this phase can be called by PHASE-1 investigation 15, 16 . Errors showed in the stage of laboratory area and finding a root cause initially in quality control area can be done by following a regulated procedure. The analyst conducting the test should report the OOS result to the supervisor the analyst and the supervisor should conduct an informal laboratory investigation which addresses the following areas: Discuss the testing procedure Discuss the calculation Examine the instruments Review the document containing the OOS result An alternative means to invalidate an initial OOS result, provided the failure investigation proves inconclusive, is the "outlier" test. However, specific restrictions must be placed on the use of this test. Firms cannot frequently reject results on this basis. The USP standards govern its use in specific cases only. The test cannot be used for chemical testing results. An initial content uniformity test was OOS followed by a passing retest. The initial OOS result was claimed the result of analyst error based on a statistical evaluation of the data. The court ruled that the use of an outlier test is inappropriate in this case. It is never appropriate to utilize outlier tests for a statistically based test, i.e., content uniformity and dissolution. Determine if the firm uses an outlier test and evaluate the SOP. Determine that a full scale inquiry has been made for multiple OOS results. This inquiry involves quality control and quality assurance personnel in addition to laboratory workers to identify exact process or nonprocess related errors. When the laboratory investigation is inconclusive (reason for the error is not identified) the firm: Cannot conduct 2 retests and base release on average of three tests Cannot use outlier test in chemical tests Cannot use a re-sample to assume a sampling or preparation error Can conduct a retest of different subject from the same sample when a retest is considered appropriate.
MATERIALS AND METHODS
Laboratory investigations
Identifying and assessing OOS test results
Phase I: laboratory investigation FDA regulations require that an investigation be conducted whenever an OOS test result is obtained (CFR 211.192) . the purpose of the investigation is to determine the cause of the OOS result. The source of the OOS result should be identified either as an aberration of the measurement process or an aberration of the manufacturing process. Even if a batch is rejected based on an OOS result, the investigation is necessary to determine if the result is associated with other batches of the same drug product or other products. Batch rejection does not negate the need to perform the investigation. The regulations require that a written record of the investigation be made, including the conclusions and follow-up.
To be meaningful, the investigation should be thorough, timely, unbiased, welldocumented, and scientifically sound. The first phase of such an investigation should include an initial assessment of the accuracy of the laboratory's data. Whenever possible, this should be done before test preparations (including the composite or the homogenous source of the aliquot tested) are discarded. This way, hypotheses regarding laboratory error or instrument malfunctions can be tested using the same test preparations. If this initial assessment indicates that no assignable causes were made in the analytical method followed during analysis, a fullscale OOS investigation should be conducted. For contract laboratories, the laboratory should convey its data, findings, and supporting documentation to the manufacturing firm's quality control unit, should then initiate the full-scale OOS investigation. The purpose is to confirm or determine the assignable cause through additional laboratory work. The documented plan should be executed and the results evaluated. It must be noted that the results obtained from the practical investigation are not "reportable results" and are for the purpose of the investigation only. Examination of the retained standard and sample solutions should be used as part of the investigation. The Phase I laboratory analysis process is represented in fig 2 below . If an assignable cause is identified, then the original suspect result is invalidated. The error is corrected, results from all affected samples are assessed, and the test is repeated. The result from the repeat test is reported and the investigation concluded. When evidence of laboratory error remains unclear, a full-scale investigation should be conducted.
Phase lA Investigation Definition
Phase IA investigation is to determine whether there has been a clear obvious error due to external circumstances such as power failure or those that the analyst has detected prior to generating data such as spilling sample that will negate the requirement of a Phase IB investigation. The Phase IA laboratory analysis process is represented in fig  3 above Incorrect Instrument Parameters for example setting the detector at the wrong wavelength, analyst and supervisor document the event, annotate "incorrect instrument parameter"; analysis to be repeated" on all associated analytical documentation. If no error was noted, and none of the above conditions were met phase IB investigation must take place. Specification A specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria which are numerical limits, ranges, or other criteria for the tests described. It establishes the set of criteria to which a drug substance, drug product or materials at other stages of its manufacture should conform to be considered acceptable for its intended use. "Conformance to specification" means that the drug substance and drug product, when tested according to the listed analytical procedures, will meet the acceptance criteria. Specifications are critical quality standards that are proposed and justified by the manufacturer and approved by regulatory authorities as conditions of approval. How the data will be evaluated For microbiological analysis where possible once a suspect result has been identified ensure all items related to the test failure are retained such as other environmental plates, dilutions, ampoules/vials of product, temperature data, auto pipettes, reagents -growth media. No implicated test environmental plates should be destroyed until the investigation has been completed. The Analyst and Supervisor investigation should be restricted to data / equipment /analysis review only On completion of the Analyst and Supervisor investigation re-measurement can start once the hypothesis plan is documented and is only to support the investigation testing. This initial hypothesis testing can include the original working stock solutions but should not include another preparation from the original sample (see: re-testing) The checklist may not be all-inclusive, but should be a good guideline to cover the pertinent areas that need to be covered in any laboratory investigation:-Correct test methodology followed e.g... Version number. Correct sample(s) taken/tested (check labels was it taken from correct place). Sample Integrity maintained, correct container and chain of custody (was there an unusual event or problem). How were sample containers stored prior to use. Correct sampling procedure followed e.g. version number. To conclude the investigation all of the results must be evaluated. The investigation report should contain a summary of the investigations performed; and a detailed conclusion. For microbiological investigations, where appropriate, use risk analysis tools to support the decisions taken and conclusions drawn. It may not have been possible to determine the actual root cause therefore a robust most probable root cause may have to be given. The batch quality must be determined and disposition decision taken. Once a batch has been rejected there is no limit to further testing to determine the cause of failure, so that corrective action can be taken. The decision to reject cannot be reversed as a result of further testing. The impact of OOS result on other batches, on-going stability studies, validated processes and testing procedures should be determined by Quality Control and Quality Assurance and be documented in the conclusion, along with appropriate corrective and preventive actions.
Regulatory Approved Specification
RESULTS AND DISCUSSION
Material OOS observed during analysis of Calcitriol API, assay by HPLC method. Product-x injection 100mg/ml (10ml), related substances test result for individual unknown impurity found to be OOS and product information is shown in 
Hypothesis study
Hypothesis study-1: analysis shall be performed by using same column and same chemicals which were used for initial analysis to establish the contribution of the column and product degradation due to chemicals or regents. Hypothesis study-2: Analysis shall be performed by using new column and same chemicals which were used for initial analysis to confirm the contribution of the column, used for initial analysis. Hypothesis study-3: Analysis shell be performed by using same column which was used for initial analysis and new chemicals to confirm the contribution of the chemicals, used for initial analysis. The above hypothesis studies are planned to evaluate the contribution from old column and chemicals, regents used for initial analysis and details of the chemicals used during initial analysis are shown in th month analysis, because the product was expired before only. As part of investigation, standard and sample and solutions are re-injected, the result of individual unknown impurity found to be an OOS and it is comparable to the initial OOS result. Based on the reinjected results proves there is no instrumental error occurred during the initial analysis. The result of hypothesis analysis is comparable to initial OOS results with respect to any other individual impurity and also it proves that the chemical and column used for the initial analysis are not contaminated. Hence to confirm the initial OOS result, analysis shall be performed in triplicate. As part of investigation performed the triplicate analysis to identify the root cause for initial OOS due to any other unspecified impurity (about RRT2.55) Triplicate analysis results are reviewed and observed that, unknown impurity at RRT 0.82 result found OOS instead of unknown impurity RRT 2.55. Based on these variation results of unknown impurities (RRT 2.55 & 0.82) the root cause for initial OOS could not be identified. Hence to confirm the OOS result observed due to unknown impurity at RRT 0.82, further investigation shall be performed. Triplicate analysis performed two times, due to during 1 st triplicate analysis PDA-detector 3D field were not used to identify a purity of peak at RRT of 0.80 hence once again performed the triplicate analysis, by using PDA-detector 3D field to identify a peak purity at RRT of 0.80peak.
